Esketamine Hydrochloride Patent Expiration

Esketamine Hydrochloride is Used for treatment-resistant depression in adults. It was first introduced by Janssen Pharmaceuticals Inc in its drug Spravato on Mar 5, 2019.


Esketamine Hydrochloride Patents

Given below is the list of patents protecting Esketamine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Spravato US10869844 Methods for the treatment of depression Sep 10, 2035 Janssen Pharms
Spravato US11173134 Methods for the treatment of depression Sep 10, 2035 Janssen Pharms
Spravato US11311500 Methods for the treatment of depression Sep 10, 2035 Janssen Pharms
Spravato US11446260 Pharmaceutical composition of S-ketamine hydrochloride Mar 14, 2034 Janssen Pharms
Spravato US11883526 Esketamine for the treatment of depression Feb 18, 2040 Janssen Pharms
Spravato US8785500 Intranasal administration of ketamine to treat depression Mar 05, 2033 Janssen Pharms
Spravato US9592207 Intranasal administration of ketamine to treat depression Mar 20, 2027 Janssen Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Esketamine Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Esketamine Hydrochloride.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 05 Jun, 2024 US10869844
Email Notification 30 Jan, 2024 US11883526
Recordation of Patent Grant Mailed 30 Jan, 2024 US11883526
Patent Issue Date Used in PTA Calculation 30 Jan, 2024 US11883526
Patent eGrant Notification 30 Jan, 2024 US11883526
Recordation of Patent eGrant 30 Jan, 2024 US11883526
Mail Patent eGrant Notification 30 Jan, 2024 US11883526
Email Notification 11 Jan, 2024 US11883526
Issue Notification Mailed 10 Jan, 2024 US11883526
Dispatch to FDC 20 Dec, 2023 US11883526



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳